Lexeo Shares Early Data On Alzheimer’s Gene Therapy
A phase i/ii study of lexeo therapeutics’ gene therapy to treat patients with alzheimer’s associated with the apoe4 genetic variant has achieved good interim results. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. In a presentation this week at the clinical trials on alzheimer's disease conference in madrid, lexeo said that within the phase i/ii study, in which 15 patients with early. The prospect of a gene therapy for alzheimer’s disease has kept wall street steadily interested in lexeo therapeutics inc. , and another increment of intrigue was added. (lxeo) wednesday reported positive interim results from the phase 1/2 study of its gene therapy candidate lx1001 for the treatment of.
Lexeo therapeutics shared biomarker data from 15 patients in a phase 1/2 study of its gene therapy for alzheimer’s.